-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Medical Announces Presentation Of Updated Pooled Results From Two First-In-Human Clinical Trials Of Alpha Dart In Pancreatic Ductal Adenocarcinoma At Digestive Disease Week

Benzinga·05/04/2026 13:24:02
Listen to the news

- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma -

- Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology -

- Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy -

- Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow -

- Results shared in oral presentation at DDW 2026, the first presentation of Alpha DaRT at a premier international gastroenterology conference -